

DR ALLAN GAW

REVIEWS ARTICLES AND BOOK CHAPTERS

To date I have written 56 review articles and book chapters, mostly on the topics of cholesterol and lipid metabolism and the clinical pharmacology of lipid regulating drugs.

Those reviews whose pdfs are in the public domain may be downloaded from the selected pdf section.

Review Articles

1. **Gaw, A.** and McKean, C.M.: Therapeutic drug monitoring. (A series of nine illustrated one page articles published monthly) *ACB News Sheet*, Feb-Oct 1989.
2. **Gaw, A.**, and Shepherd, J.: Combination drug therapy for hyperlipidaemia. *Journal of Drug Development* 3(Suppl. 1): 227–231, 1990.
3. **Gaw, A.**, Griffin, B.A., Gaffney, D., Caslake, M.J., Packard, C.J., and Shepherd, J.: Genetic and environmental modulation of low-density lipoprotein catabolism. *Biochemical Society Transactions* 18: 1072–1074, 1990.
4. **Gaw, A.**, and Shepherd, J.: Fibric acid derivatives. *Current Opinion in Lipidology* 2: 39–42, 1991.
5. Shepherd, J., Griffin, B., Caslake, M., **Gaw, A.**, and Packard, C.: The influence of fibrates on lipoprotein metabolism. *Atherosclerosis Reviews*. 22: 163-169, 1991.
6. **Gaw, A.**, Packard, C.J., and Shepherd, J.: VLDL and LDL turnover: methods and clinical application. *Current Opinion in Lipidology* . 3: 384–388, 1992.
7. **Gaw, A.**: New lipid lowering drugs. *G.P. Update* April 669–677, 1992.
8. Shepherd, J., Caslake, M., **Gaw, A.**, Griffin, B., Lindsay, G., and Packard, C. Atherogenicity of triglyceride rich lipoproteins. *Annales de Biologie Clinique* 51: 260-262, 1993
9. Hobbs, H.H., Chiesa, G., **Gaw, A.**, Lawn, R., Maika, S., Koschinsky, M., and Hammer, R.: Apo (a) expression in transgenic mice. *Annals of the New York Academy of Science* 714: 231-236, 1994.
10. **Gaw, A.** and Hobbs, H.H.: Molecular genetics of Lp(a) - new pieces to the puzzle. *Current Opinion in Lipidology* 5: 149-155, 1994.
11. **Gaw, A.**, Packard, C.J. and Shepherd, J.: Fibrates: pharmacology and clinical application. *Cardiovascular Risk Factors*. 5: 45-56, 1995.
12. O'Reilly, D. St.J., Cowan, R.A., and **Gaw, A.** The interpretation of thyroid function tests. *Student BMJ* 3: 447-449, 1995.

13. **Gaw, A.** Lipoprotein (a): molecular genetics and cardiovascular risk. *Fundacja Rozwoju Diagnostyki Laboratoryjnej (Journal of Polish Society of Laboratory Diagnostics)*, 1: 101-117, 1996.
14. Cowan, R.A., O'Reilly, D. St.J., and **Gaw, A.** How to diagnose hypercalcaemia I. *Student BMJ* 4: 95-97, 1996.
15. Cowan, R.A., O'Reilly, D. St.J., and **Gaw, A.** How to diagnose hypercalcaemia-II. Hypercalcaemia of malignancy. *Student BMJ* 4: 142-143, 1996.
16. **Gaw, A.**, and Demant, T. Apolipoprotein-B metabolism in primary and secondary hyperlipidaemias. *Current Opinion in Lipidology* 7: 149-154, 1996.
17. **Gaw, A.** Lipoprotein metabolism: bimonthly review. *Current Opinion in Lipidology* 7: U49-U56, 1996.
18. **Gaw, A.** How are statins best applied? *Costs & Options in Hyperlipidaemia*, Issue 13, 1997.
19. **Gaw, A.**, and Shepherd, J.: Identifying and treating those at risk: new evidence from the West of Scotland Coronary Prevention Study. *Cardiovascular Risk Factors* 8: 12-19, 1998.
20. **Gaw, A.** Evidence based approach for the management of mixed hyperlipidaemia. *Atherosclerosis*, 137 (Suppl). 97-100, 1998.
21. **Gaw, A.**, and Packard C.J. At what level of coronary heart disease risk should a statin be prescribed? *Current Opinion in Lipidology*, 11: 363-367, 2000.
22. **Gaw, A.** Simvastatin: building on success. *Hospital Medicine*, 62: 29-32, 2001.
23. Pedersen, T. and **Gaw, A.** Statins – similarities and differences. *American Journal of Managed Care* 7 (5Suppl): S132-S137, 2001.
24. **Gaw, A.** Healthy ageing: addressing acute coronary syndrome? *European Heart Journal Supplements* 3 (Suppl N): N11-N15, 2001.
25. **Gaw, A.** The statin benefit. *Scottish Primary Care* 12: 12-13, 2001.
26. **Gaw, A.** A new reality: achieving cholesterol-lowering goals in clinical practice. *Atherosclerosis* Suppl 2: 5-11, 2002.
27. **Gaw, A.** Primary prevention: a simple, effective means of risk reduction. *International Journal of Clinical Practice* Suppl 130: 6-12, 2002.
28. Shepherd, J. and **Gaw, A.** The Anatomy of a Clinical Trial: The West of Scotland Coronary Prevention Study. *Medical Principles and Practice*.2: 17-30, 2002.
29. Mungall, M.M.B., **Gaw, A.**, Shepherd J. Statin therapy in the elderly: does it make good clinical and economic sense? *Drugs and Aging* 20: 263-275, 2003.
30. **Gaw, A.** HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins. *Cardiovascular Drugs and Therapy* 17: 53-62, 2003.

31. **Gaw, A.** Coronary heart disease prevention: the role of statin therapy. *Scottish Nurse* 8: 34-35, 2003.
32. Mungall, M.M.B., **Gaw, A.** Statin use: what is the evidence base? *Geriatric Medicine* November, 2003.
33. Kent JA, Dinnett JA, McIntyre K, Mungall MMB, Ronald ES, **Gaw A.** Roles for nurses in clinical trials – new challenges, new opportunities. *Scottish Nurse* 8(9): 30-31, 2004.
34. Mungall, M.M.B., **Gaw, A.** Statin therapy in the elderly. *Current Opinion in Lipidology*, 15: 453-457, 2004.
35. **Gaw, A.** The care gap: underuse of statin therapy in the elderly. *International Journal of Clinical Practice* August 2004.
36. McIntyre KE, Dinnett EM, Mungall MMB, Ronald ES, Kent JA, **Gaw A.** Selecting investigators in primary care – what to look for; what to avoid. *Clinical Research Focus* 15(4): 38-43, 2004.
37. **Gaw, A.** Rosuvastatin: achieving cholesterol targets. *Future Cardiology* 1: 289-297, 2005.
38. **Gaw, A.** Beyond consent: the potential for atrocity. *Journal of the Royal Society of Medicine*, 99: 175-177, 2006.
39. **Gaw, A.** Should we be targeting triglyceride as well as LDL cholesterol in the battle against coronary heart disease? *Nature Clinical Practice Cardiovascular Medicine*, 5: 438-9, 2008.

BOOK CHAPTERS

1. **Gaw, A.**, Packard, C.J., and Shepherd, J.: *Lipoprotein turnover and metabolism*. Chapter 5 (p119–144) In: *Lipoprotein Analysis. A Practical Approach*. (Ed Converse, C.A. and Skinner, E.R.). IRL Press at Oxford University Press. 1992.
2. **Gaw, A.**, Stewart, J.P., Pappu, A.S., Illingworth, D.R., Vallance, B.D., Packard, C.J., and Shepherd, J.: *Urinary mevalonic acid and plasma lathosterol: Responses to fenofibrate therapy*. Chapter 130 In: *Molecular Biology of Atherosclerosis* (Ed. M.J. Halpern), John Libbey and Co., Ltd., London, 1992.
3. **Gaw, A.**, Packard, C.J., and Shepherd, J.: *Fibrates*. Chapter 12 (p325-348) In: *Handbook of Experimental Pharmacology Vol: 109 Principles and Treatment of Lipoprotein Disorders* (Eds. Schettler, G., Habenicht, A.J.R.) Springer-Verlag, Munich, 1994.
4. **Gaw, A.**, Packard, C.J., and Shepherd, J.: *Lipids and atherosclerosis*. Chapter 50 (p1153-1168) In: *Haemostasis and Thrombosis* 3rd Ed. (Eds Bloom, A.L., Forbes C.D., Thomas, D.P., and Tuddenham E.G.D.) Churchill Livingstone, Edinburgh, 1994.

5. **Gaw, A.** and Hobbs, H.H.: Lipoprotein (a). Chapter 6 pp 87-109 In: *Lipoproteins in Health and Disease*. (Eds. Betteridge, D.J., Illingworth, D.R., and Shepherd, J.) Edward Arnold, London, 1999.
6. **Gaw, A.** and Packard, C.J.: *Investigation of lipoprotein metabolism*. Chapter 27 pp 491-521 In: *Lipoproteins in Health and Disease*. (Eds. Betteridge, D.J., Illingworth, D.R., and Shepherd, J.) Edward Arnold, London, 1999.
7. Shepherd, J and **Gaw, A.**: Fenofibrate. Chapter 117 pp 1083-1092 In: *Cardiovascular Drug Therapy* 2nd Edn (Ed. Messerli, F.H.) . B. Saunders Company, Philadelphia, 1999.
8. **Gaw, A.**, Lindsay, G.M., and Shepherd, J.: *Atherosclerosis*. Chapter 8 In: *Mechanisms of Disease*. (Eds. Tomlinson, S., Hegarty, A.M., and Weetman, A.P.) Cambridge University Press, Cambridge, 1997.
9. **Gaw, A.** *Lipid lowering drug therapy*. Chapter 10 in: Lindsay, G.M. and Gaw, A. (eds) *Coronary heart Disease Prevention: A Handbook for the Healthcare Team*, Churchill Livingstone, Edinburgh, 1997.
10. **Gaw, A.** and Shepherd, J. *Cholesterol and lipoproteins*. Chapter 3 in: Lindsay, G.M. and Gaw, A. (eds) *Coronary heart Disease Prevention: A Handbook for the Healthcare Team*, Churchill Livingstone, Edinburgh, 1997.
11. **Gaw, A.** and Shepherd J.: *Fibric Acid Derivatives*. Chapter 65 pp 1145-1160 In: *Lipoproteins in Health and Disease*. (Eds. Betteridge, D.J., Illingworth, D.R., and Shepherd, J.) Edward Arnold, London, 1999.
12. **Gaw, A.** and Shepherd, J. *Management of Dyslipidaemias in Diabetes*. In: *Diabetes Annual 11th Volume*. (Eds Marshall, S.M., Home, P.D. and Rizza, R.) 1998.
13. **Gaw, A.** & Shepherd J. *The West of Scotland Coronary Prevention Study*. Chapter 4 In: *Cholesterol Lowering Therapies* (Ed S.M. Grundy) Marcel Dekker Inc, New York 1999.
14. Packard, C.J., **Gaw, A.**, and Shepherd, J. *Cholesterol-lowering agents and their use*, version 1.0. In: *Encyclopedia of Life Sciences*. London: Nature Publishing Group. [doi: 10.1038/npg.els.0002265] <http://www.els.net/> 2003.
15. **Gaw, A.** , Packard, C.J. & Shepherd J. *Lipid and lipid-modifying therapy*. Chapter 3 In: *Atherosclerosis and Heart Disease* (Ed. A. Tonkin) Martin Dunitz, London, 2004.
16. Mungall, M.M.B. and **Gaw, A.** *Lipids and lipid-modifying therapy*. Chapter 7 In: *Men's Health 2nd Edn*, (Eds. Kirby RS, Carsson CC, Kirby MG & Farah RN, Martin Dunitz) London, 2004.
17. **Gaw, A.** Lipids and lipid lowering drugs. Chapter 3 in: *Coronary heart Disease Prevention: A Handbook for the Healthcare Team 2nd Edn*, (Eds. Lindsay, G.M. and Gaw, A.) Churchill Livingstone, Edinburgh, 2004.